Effects of Proton Pump Inhibitors and<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msub><mml:mtext>H</mml:mtext><mml:mn mathvariant="bold">2</mml:mn></mml:msub></mml:mrow></mml:math>Receptor Antagonists on the Ileum Motility

Kurt, Atilla; Altun, Ahmet; Bağcıvan, İhsan; Koyuncu, Ayhan; Topçu, Ömer; Aydın, Cengiz; Kaya, Tijen

doi:10.1155/2011/218342

Cited by 6 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The PPI-induced reduction in LES tone is not unique to gastroesophageal muscle, since these compounds have been shown to relax all smooth muscle preparations where their effect was evaluated. These include the human myometrium (27,33), bladder muscle (19), and myocardium (24,26), as well as animal tissue intestinal (14), vascular (12), airway (21), and gallbladder (1) smooth muscle and corpus cavernosum (23).…”

Section: Discussionmentioning

confidence: 99%

Pantoprazole decreases gastroesophageal muscle tone in newborn rats via rho-kinase inhibition

Welsh

Kasirer

Pan

et al. 2014

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

Proton pump inhibitors reduce gastric acid secretion and are commonly utilized in the management of gastroesophageal reflux disease across all ages. Yet a decrease in lower esophageal sphincter tone has been reported in vitro in rats through an unknown mechanism; however, their effect on the gastroesophageal muscle tone early in life was never studied. Hypothesizing that proton pump inhibitors also reduce gastroesophageal muscle contraction in newborn and juvenile rats, we evaluated the in vitro effect of pantoprazole on gastric and lower esophageal sphincter muscle tissue. Electrical field stimulation and carbachol-induced force were significantly (P < 0.01) reduced in the presence of pantoprazole, whereas the drug had no effect on the neuromuscular-dependent relaxation. When administered in vivo, pantoprazole (9 mg/kg) significantly (P < 0.01) reduced gastric emptying time at both ages. To ascertain the signal transduction pathway responsible for the reduction in muscle contraction, we evaluated the tissue ROCK-2 and CPI-17 activity. Pantoprazole reduced myosin light chain phosphatase MYPT-1, but not CPI-17 phosphorylation of gastric and lower esophageal sphincter tissue, strongly suggesting that it is a ROCK-2 inhibitor. To the extent that these findings can be extrapolated to human neonates, the use of pantoprazole may impair gastric and lower sphincter muscle tone and thus paradoxically exacerbate esophageal reflux. Further studies addressing the effect of proton pump inhibitors on gastroesophageal muscle contraction are warranted to justify its therapeutic use in gastroesophageal reflux disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Pantoprazole decreases gastroesophageal muscle tone in newborn rats via rho-kinase inhibition

Welsh

Kasirer

Pan

et al. 2014

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

show abstract

“…Stress ulcer prophylaxis with pantoprazole was administered to patients above three years of age. Short-term treatment with proton pump inhibitors (PPIs) has been reported to delay gastric emptying of solid meals in healthy individuals (22). The effects of PPIs on liquid emptying are inconsistent (23).…”

Section: Discussionmentioning

confidence: 99%

Delineating Gastrointestinal Dysfunction Variants in Severe Burn Injury Cases: A Retrospective Case Series with Literature Review

Rapaka,

Datta,

Sharma

2024

Southwest J Pulm Crit Care Sleep

View full text Add to dashboard Cite

Background: Severe burns can significantly impact various organ systems, including the gastrointestinal (GI) system. GI complications are frequently observed in patients with over 20% total body surface area (TBSA) burn. Objectives: This case series delves into the intricate phenomenology of post-burn GI dysfunction, challenging conventional cause-and-effect paradigms. Our aim is to discern, comprehend, and explore variables influencing positive and negative outcomes, laying the foundation for further research given the current heterogeneity in the literature. Methods: Severe burn patients with GI dysfunction identified between April 1, 2022, and July 31, 2022, from the institutional database are included in this retrospective case-series, and comparisons were made across baseline and treatment conditions across participants. Data were collected on demographics, burn characteristics, complications, and treatment outcomes. Results: We analysed 12 patients with severe burns and GI dysfunction and categorized them into two patterns: Pattern A, characterised by early onset symptoms, gastric and small bowel dilatation, and a relatively benign course with high recovery rates was observed in 6 patients; and Pattern B, characterised by late-onset symptoms, colonic dilatation, shock, and a high mortality rate due to megacolon was seen in 6 patients. Conclusion: The post-burn GI dysfunction observed in our study is a complex interplay of multiple factors. Adequate fluid resuscitation, timely excision of necrotic tissue, staged food ingestion, specific nutrient administration, and appropriate use of antibiotics and judicious use of selective digestive decontamination (SDD) are essential strategies to prevent and treat this syndrome.

show abstract

“…27 Several studies also show that PPIs may decrease motility in the gastrointestinal tract, but H 2 RA has some prokinetic properties due to its anticholinesterase activity. [28][29][30] Both gastric acid suppression and bowel dysmotility are risk factors for intestinal bacterial overgrowth. 31 Thus, cirrhotic patients who received H 2 RA had lower risk of SBP development than those using PPIs, making H 2 RA an acceptable alternative for treating mild acid-related disease.…”

Section: Discussionmentioning

confidence: 99%

Association of gastric acid suppressants with the development of spontaneous bacterial peritonitis in cirrhotic patients with ascites

Teng

Hsu

et al. 2019

Adv in Digestive Medicine

View full text Add to dashboard Cite

The study aimed to characterize the association of gastric acid suppressants (GAS) with the development of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites. A retrospective case controlled study from January 2013 to December 2017 at Cheng‐Ching General Hospital was conducted. We included patients with a diagnosis of liver cirrhosis with ascites, divided into those with and without SBP. SBP was defined by ascitic fluid polymorphonuclear cell level. GAS users were patients who received GAS daily for more than 7 days in the 90 days before admission. Of 229 cirrhotic patients enrolled, 60 had SBP and 169 did not. The groups differed significantly in albumin (P = .045) and total bilirubin (P = .016) levels; in international normalized ratio (P = .007) and proton pump inhibitor (PPI) use (P = .021); but not in histamine‐2 receptor antagonist (H2RA) use. Multivariate analysis identified PPI use as the only independent risk factor for SBP development (odds ratio 2.101, 95% confidence interval 1.122‐3.935, P = .02). PPIs but not H2RAs may increase the incidence of SBP in cirrhotic patients with ascites. Prescribing PPIs in cirrhotic patients should be done carefully, for the minimal effective treatment duration.

show abstract

Effects of Proton Pump Inhibitors andH2Receptor Antagonists on the Ileum Motility

Cited by 6 publications

References 23 publications

Pantoprazole decreases gastroesophageal muscle tone in newborn rats via rho-kinase inhibition

Pantoprazole decreases gastroesophageal muscle tone in newborn rats via rho-kinase inhibition

Delineating Gastrointestinal Dysfunction Variants in Severe Burn Injury Cases: A Retrospective Case Series with Literature Review

Association of gastric acid suppressants with the development of spontaneous bacterial peritonitis in cirrhotic patients with ascites

Contact Info

Product

Resources

About